DC-IBEX
6.6.2019 16:43:05 CEST | Business Wire | Press release
ibex, a global leader in customer experience solutions, is expanding its presence with the opening of three new sites in the Philippines. Two of the sites are in Metro Manila and the third in Bohol, a provincial island in the Philippines. The announcement comes weeks after ibex was named Nearshore Company of the Year by Nearshore Americas based on their leadership position in nearshore regions and the explosive growth the company is currently experiencing in Jamaica and Nicaragua.
“ibex continues to define itself as the growth leader in the BPO space,” said Bob Dechant, CEO of ibex. “The growth we are experiencing is the result of excellent performance, a great leadership team and most importantly a corporate culture where employees are valued and engaged. This has enabled us to win marquee new clients while growing market share with our current clients.”
ibex anticipates hiring 3,000 employees across the three locations. The company already has three sites in Metro Manila and one in Davao. This will bring the total number of ibex employees to over 10,000 in the Philippines.
“The three new sites are the result of rapid client growth,” continued Dechant. “One of the Metro Manila locations will be a mega-site for one of our largest clients and the other will be the location for the additional clients we have recently won. The third site in Bohol, gives us the opportunity to be the first call center to locate in the region. Given the high education level of the labor pool, a world class client, exceptional government support and a new international airport, ibex is confident about growing the BPO industry in this new, important region.”
The Alabang site will open mid-June and is part of Metro Manila and south of the city. Once a farming district, it is now a bustling commercial center. Bohol will launch in early August. Bohol is located in the Central Visayas region, consisting of the main island and 75 surrounding minor islands. The third location Cyberpark is in a district called Cubao in Quezon City, part of the province of Luzon in Metro Manila and will be operational by late August.
About ibex
ibex is a privately held technology and customer engagement company specializing in helping global brands add, engage, and keep customers. With CLX, the Customer Lifecycle Experience suite, ibex offers advanced digital marketing technology, a 26-site worldwide BPO network, and omnichannel CX platforms to help clients accelerate growth, decrease costs, and motivate valuable brand assets anywhere along the customer lifecycle. ibex is headquartered in Washington, DC, and currently has 19,000+ employees.
View source version on businesswire.com: https://www.businesswire.com/news/home/20190606005535/en/
Contact:
Rosemary Hanratty Rosemary.hanratty@ibex.co 412-539-7099
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Vonage Expands Developer Ecosystem to Accelerate the Next Era of Enterprise Digital Transformation19.2.2026 10:08:00 CET | Press release
Vonage verified Postman workspace extends reach by 40+ million developers; MCP servers and Startup Program among resources designed to further accelerate time-to-value for developers and enterprises Vonage, part of Ericsson (NASDAQ: ERIC), today announced a number of new initiatives, to further expand and enable its global developer community. By growing its developer community and tools, giving developers and enterprises access to new mobile network insights and capabilities that can be embedded into existing applications and workflows, Vonage is accelerating its strategy to transform mobile networks into a programmable platform. Putting Vonage APIs in the Hands of 40 million+ More Developers Vonage is announcing the launch of its Verified Workspace on the Postman API Network, making Vonage APIs available to the 40+ million developers who use Postman. The new, verified workspace gives Postman’s community of global developer members certified access to Vonage’s portfolio of Network API
Brenus Pharma Presented New Preclinical and Early Clinical Data in Colorectal Cancer During AACR Immuno-Oncology Conference 202619.2.2026 08:50:00 CET | Press release
Brenus Pharma, a clinical-stage biotechnology company pioneering in vivo “off-the-shelf” immunotherapies, announced the selection of an abstract for a poster presentation at the American Association for Cancer Research Immuno-Oncology (AACRIO) annual conference (February 18-21, 2026), in Los Angeles. The poster showcases new preclinical data and early clinical insights from the company's lead candidate, STC-1010, supporting it as a promising therapeutic option for MSS, immune-cold colorectal cancer (CRC)—a major unmet clinical need. In a syngeneic CT26 model, murine STC-1010 significantly inhibits tumor growth and extends survival by 40%. New mechanistic datas reveal expansion of CD4⁺ and CD8⁺ T cells in draining lymph nodes alongside a significant humoral response compared to control, demonstrating coordinated cellular and humoral immune activation in vivo. Other findings show that dendritic cells efficiently capture STC-1010, leading to their activation as demonstrated by transcripto
ENHERTU® Type II Variation Application Validated in the EU as Post-Neoadjuvant Treatment for Patients with HER2 Positive Early Breast Cancer19.2.2026 08:30:00 CET | Press release
Based on DESTINY-Breast05 phase 3 trial results, which showed ENHERTU reduced the risk of invasive disease recurrence or death by 53% compared to T-DM1 If approved, Daiichi Sankyo and AstraZeneca’s ENHERTU has the potential to become a new standard of care in this early breast cancer setting The European Medicines Agency (EMA) has validated the Type II Variation marketing authorization application for ENHERTU® (trastuzumab deruxtecan) as a monotherapy for adult patients with HER2 positive (immunohistochemistry [IHC] 3+ or in-situ hybridization [ISH]+) breast cancer who have residual invasive disease after neoadjuvant HER2 targeted treatment. ENHERTU is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The validation confirms the completion of the application and commences the scientific review process by the EMA’s Committ
NHOA Energy Advances Delivery of the 51 MWh Broni Battery for Neoen in Italy19.2.2026 08:00:00 CET | Press release
The project confirms NHOA Energy’s long-term commitment to the Italian market NHOA Energy, global provider of utility-scale energy storage systems, is advancing the construction of the Broni Battery, a 10 MW/51 MWh project located in Broni (Pavia), Italy, executed for Neoen, one of the world’s leading independent producers of renewable energy. Civil works at the site are currently underway and advancing on schedule, with commissioning activities planned to start in late spring 2026. Once operational, the Broni Battery will provide essential flexibility services to the Italian electricity system, supporting grid stability and reliability as renewable energy penetration continues to increase. The project represents Neoen’s first battery storage asset in Italy and marks a strategic step in the company’s expansion, as it continues to grow its battery storage portfolio in key markets worldwide to support power system flexibility. The Broni Battery further strengthens NHOA Energy’s long-term
Compass Pathways Announces Pricing of $150 Million Public Offering19.2.2026 02:18:00 CET | Press release
Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation, announced today the pricing of its public offering of 17,500,000 American Depositary Shares (“ADSs”) at a public offering price of $8.00 per ADS, each representing one ordinary share, and in lieu of ADSs, to certain institutional investors, pre-funded warrants to purchase up to 1,250,000 ADSs at a public offering price of $7.9999 per pre-funded warrant. In addition, Compass Pathways has granted the underwriters a 30-day option to purchase up to an additional 2,812,500 ADSs at the public offering price, less the underwriting discounts and commissions. All of the securities are to be sold by Compass Pathways. The offering is expected to close on or about February 20, 2026, subject to the satisfaction of customary closing conditions. The gross proceeds to Compass Pathways from the offering, before deducting underwriting discounts and commissions and other est
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom